Crystec applies the latest modified supercritical antisolvent (mSAS) technology to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technology can be applied to small and large drug molecules in a range of dosage forms.

Our services include crystal form screening and particle design (including composite particles and co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels. We are also engaged in in-house programmes to develop improved products and currently have licensing opportunities available in several therapeutic areas, including urge incontinence, fungal infections, and malaria.

The first product based on this technology platform is an inhaled product for migraine which has progressed to marketing authorisation application stage – supercritical antisolvent processing enables exceptional particle size control and lung deposition resulting in rapid uptake. Particle design and scale-up to GMP for this product were managed by members of the Crystec team.